Breaking News

ObsEva, Syneos Health Partner to Commercialize Linzagolix

Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ObsEva SA, a biopharmaceutical company dedicated to women’s reproductive health, entered a strategic relationship with Syneos Health, an integrated CRO for biopharmaceutical services, to commercialize linzagolix.   Linzagolix has the potential to be a best-in-class GnRH receptor antagonist for the treatment of uterine fibroids due to its efficacy and favorable tolerability profile. If approved, it would be the only GnRH antagonist for uterine fibroids with flexible dosing options, as well as t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters